A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent

Por Sharma, Padmanee, Grimm, Marc-Oliver, Galsky, Matthew D, Baron, Ari, Bracarda, Sergio, Siefker-Radtke, Arlene, Lambert, Alexandre, Azrilevich, Alex, Retz, Margitta
Publicado no J Immunother Cancer (2015)

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase ch...

Por Shah, Neil P., Kim, Dong-Wook, Kantarjian, Hagop, Rousselot, Philippe, Llacer, Pedro Enrique Dorlhiac, Enrico, Alicia, Vela-Ojeda, Jorge, Silver, Richard T., Khoury, Hanna Jean, Müller, Martin C., Lambert, Alexandre, Matloub, Yousif, Hochhaus, Andreas
Publicado em 2010

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Por Motzer, Robert J., Rini, Brian I., McDermott, David F., Redman, Bruce G., Kuzel, Timothy M., Harrison, Michael R., Vaishampayan, Ulka N., Drabkin, Harry A., George, Saby, Logan, Theodore F., Margolin, Kim A., Plimack, Elizabeth R., Lambert, Alexandre M., Waxman, Ian M., Hammers, Hans J.
Publicado no J Clin Oncol (2015)